Amylyx Pharmaceuticals, Inc. (AMLX) Balance Sheet
As of 2026-06-30 (10-Q), Amylyx Pharmaceuticals, Inc. (AMLX) reported total assets of $264.6M, total liabilities of $25.4M and shareholders' equity of $239.2M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $49.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AMLXAmylyx Pharmaceuticals, Inc.Follow AMLX — free
—
Price chart with a free account
- Market cap
- 3.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Cash and equivalents | 62.5 | 170.2 | 77.4 | 226.7 | 49.3 | |
| Short-term investments | 284.4 | 201.2 | 99.1 | 90.3 | 201.4 | |
| Receivables | 15.3 | 40.1 | 0.4 | 0.1 | — | |
| Inventory | 0.9 | 11.2 | 0.0 | — | — | |
| Current assets | 382.1 | 464.7 | 189.4 | 323.7 | 256.3 | |
| Total assets | 391.5 | 517.5 | 193.6 | 332.6 | 264.6 | |
| Current liabilities | 46.6 | 82.0 | 28.4 | 22.7 | 21.2 | |
| Total liabilities | 50.8 | 84.0 | 28.9 | 27.4 | 25.4 | |
| Shareholders' equity | 340.6 | 433.4 | 164.8 | 305.3 | 239.2 |
USD millions · SEC XBRL
Amylyx Pharmaceuticals, Inc. — questions
- How much cash does Amylyx Pharmaceuticals, Inc. have?
- $49.3M in cash and cash equivalents as of 2026-06-30.
- What are Amylyx Pharmaceuticals, Inc.'s total assets?
- $264.6M as of 2026-06-30.
- What is Amylyx Pharmaceuticals, Inc.'s shareholders' equity?
- $239.2M as of 2026-06-30.
Every figure on this page comes from Amylyx Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.